Early attempts followed a traditional approach to vaccination where normal S. mutans was introduced to promote a reaction from the immune system, stimulating antibody production [REF].
The corporation Planet Biotechnology has developed a synthetic antibody against S. mutans, branded CaroRx, which it produces using transgenic tobacco plants.